XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.3

Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Sales Category

The following tables provide detail by sales category:

						Three Months Ended September 30, 2025																		Three Months Ended September 30, 2024
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	1,097					$	1,097					$	—					$	994					$	994
Other						—						414						414						—						412						412
Total						—						1,511						1,511						—						1,406						1,406
Nutritional Products —
Pediatric Nutritionals						520						457						977						568						387						955
Adult Nutritionals						368						808						1,176						382						729						1,111
Total						888						1,265						2,153						950						1,116						2,066
Diagnostic Products —
Core Laboratory						366						998						1,364						332						982						1,314
Molecular						36						95						131						37						91						128
Point of Care						111						47						158						103						43						146
Rapid Diagnostics						373						227						600						560						264						824
Total						886						1,367						2,253						1,032						1,380						2,412
Medical Devices —
Rhythm Management						350						336						686						288						309						597
Electrophysiology						322						383						705						285						325						610
Heart Failure						280						86						366						252						70						322
Vascular						280						465						745						258						441						699
Structural Heart						297						338						635						270						288						558
Neuromodulation						196						58						254						190						46						236
Diabetes Care						796						1,261						2,057						673						1,052						1,725
Total						2,521						2,927						5,448						2,216						2,531						4,747
Other						4						—						4						4						—						4
Total						$	4,299					$	7,070					$	11,369					$	4,202					$	6,433					$	10,635

						Nine Months Ended September 30, 2025																		Nine Months Ended September 30, 2024
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	3,121					$	3,121					$	—					$	2,910					$	2,910
Other						—						1,033						1,033						—						1,016						1,016
Total						—						4,154						4,154						—						3,926						3,926
Nutritional Products —
Pediatric Nutritionals						1,695						1,377						3,072						1,646						1,377						3,023
Adult Nutritionals						1,105						2,334						3,439						1,115						2,146						3,261
Total						2,800						3,711						6,511						2,761						3,523						6,284
Diagnostic Products —
Core Laboratory						1,049						2,850						3,899						969						2,879						3,848
Molecular						111						265						376						112						272						384
Point of Care						315						133						448						308						133						441
Rapid Diagnostics						1,093						664						1,757						1,386						762						2,148
Total						2,568						3,912						6,480						2,775						4,046						6,821
Medical Devices —
Rhythm Management						994						950						1,944						851						915						1,766
Electrophysiology						943						1,091						2,034						841						983						1,824
Heart Failure						824						249						1,073						733						215						948
Vascular						831						1,381						2,212						787						1,325						2,112
Structural Heart						868						980						1,848						761						876						1,637
Neuromodulation						565						171						736						563						142						705
Diabetes Care						2,338						3,527						5,865						1,899						3,043						4,942
Total						7,363						8,349						15,712						6,435						7,499						13,934
Other						12						—						12						11						—						11
Total						$	12,743					$	20,126					$	32,869					$	11,982					$	18,994					$	30,976

Schedule of Changes in Contract Liabilities

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2024						$	568
Unearned revenue from cash received during the period						382
Revenue recognized related to contract liability balance						(300)
Balance at September 30, 2025						$	650

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration